Paper41003131
Irvine-Gass Syndrome Personalized Treatment Outcomes: A Retrospective Single-Center Cohort Study.
Tomaschek L and 5 others. J Pers Med, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Irvine-Gass Syndrome Personalized Treatment Outcomes: A Retrospective Single-Center Cohort Study. Papers, record 41003131. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41003131
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Irvine-Gass Syndrome Personalized Treatment Outcomes: A Retrospective Single-Center Cohort Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39446879 | Pseudophakic cystoid macular edema. | Curr Opin Ophthalmol | 2025 | https://conductscience.org/library/papers/39446879 | PubMed |
| 2 | 27190126 | Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. | Br J Ophthalmol | 2017 | https://conductscience.org/library/papers/27190126 | PubMed |
| 3 | 35372711 | Improvement of pseudophakic cystoid macular edema with subconjunctival injections of interferon α2b:a case report. | Am J Ophthalmol Case Rep | 2022 | https://conductscience.org/library/papers/35372711 | PubMed |
| 4 | 33078109 | Comparison of intravitreal anti-vascular endothelial growth factor agents and treatment results in Irvine-Gass syndrome. | Int J Ophthalmol | 2020 | https://conductscience.org/library/papers/33078109 | PubMed |
| 5 | 32967137 | Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac. | J Clin Med | 2020 | https://conductscience.org/library/papers/32967137 | PubMed |
| 6 | 31179657 | Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema. | Korean J Ophthalmol | 2019 | https://conductscience.org/library/papers/31179657 | PubMed |
| 7 | 39354377 | Clinical macular edema following uneventful cataract surgery in eyes without pre-existing fundus diseases: risk factors and treatment prognosis. | BMC Ophthalmol | 2024 | https://conductscience.org/library/papers/39354377 | PubMed |
| 8 | 34427221 | Topical interferon - A novel treatment for pseudophakic macular edema. | Indian J Ophthalmol | 2021 | https://conductscience.org/library/papers/34427221 | PubMed |
| 9 | 28366377 | Treatment of cystoid macular edema after cataract surgery. | J Cataract Refract Surg | 2017 | https://conductscience.org/library/papers/28366377 | PubMed |
| 10 | 39976161 | Prevention and management of postcataract cystoid macular edema. | Curr Opin Ophthalmol | 2025 | https://conductscience.org/library/papers/39976161 | PubMed |
| 11 | 34640393 | Current Management Options in Irvine-Gass Syndrome: A Systemized Review. | J Clin Med | 2021 | https://conductscience.org/library/papers/34640393 | PubMed |
| 12 | 30986123 | Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome). | Ocul Immunol Inflamm | 2020 | https://conductscience.org/library/papers/30986123 | PubMed |
| 13 | 35252233 | Efficacy of Intravitreal Injection of Filtered Modified Low-Dose Triamcinolone Acetonide and Ranibizumab on Pseudophakic Cystoid Macular Edema. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35252233 | PubMed |
| 14 | 29346240 | RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE. | Retina | 2019 | https://conductscience.org/library/papers/29346240 | PubMed |
| 15 | 26681390 | Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. | Ophthalmology | 2016 | https://conductscience.org/library/papers/26681390 | PubMed |
| 16 | 26560833 | Incidence and Characteristics of Cystoid Macular Edema after Cataract Surgery. | Ophthalmology | 2016 | https://conductscience.org/library/papers/26560833 | PubMed |
| 17 | 38490455 | Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review. | Surv Ophthalmol | 2024 | https://conductscience.org/library/papers/38490455 | PubMed |
| 18 | 31313428 | Topical non-steroidal anti-inflammatory drugs are not the mainstay of prophylaxis and treatment for pseudophakic cystoid macular oedema. | Clin Exp Ophthalmol | 2019 | https://conductscience.org/library/papers/31313428 | PubMed |
| 19 | 18370876 | Preservative-free triamcinolone acetonide suspension developed for intravitreal injection. | J Ocul Pharmacol Ther | 2008 | https://conductscience.org/library/papers/18370876 | PubMed |
| 20 | 20559157 | Novel method for analyzing snellen visual acuity measurements. | Retina | 2010 | https://conductscience.org/library/papers/20559157 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CST12P | 106478911 | PubTator's text mining | https://conductscience.org/library/genes/106478911 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41003131
GET https://conductscience.org/api/papers/v1/41003131/references?page=2